Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1122435

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1122435

Typhoid Fever Vaccines Market, by Vaccine Type, by Route of Administration, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

PUBLISHED:
PAGES: 177 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea. The bacterium usually enters the body through the mouth by the ingestion of contaminated food or water, penetrates the intestinal wall, and multiplies in lymphoid tissue. It then enters the bloodstream and causes bacteremia. People who drink contaminated water or eat food washed in contaminated water can develop typhoid fever. Typhoid fever is majorly caused in area with poor sanitation and lack of clean drinking water. Typhoid fever vaccines are the biological formulations, which provide immunity and protect an individual against typhoid fever.

Currently there are three typhoid vaccines recommended by the World Health organization (WHO) for use which include:

  • Injectable typhoid conjugate vaccine (TCV), consisting of Vi polysaccharide antigen linked to tetanus toxoid protein licensed for children from 6 months of age and adults up to 45 years of age
  • Injectable unconjugated polysaccharide vaccine based on the purified Vi antigen (known as Vi-PS vaccine) for persons aged two years and above, and
  • Oral live attenuated Ty21a vaccine in capsule formulation for those over six years of age

Market Dynamics

Increasing initiatives by governments and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to drive the typhoid fever vaccines market growth during forecast period. For instance, in February 2019, Gavi, the Vaccine Alliance in partnership with WHO, Center for Disease Control and Prevention and Zimbabwe's Ministry of Health launched a campaign to tackle typhoid outbreak in Zimbabwe. Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world's children against some of the world's deadliest diseases. The campaign aims to vaccinate 325,000 people in nine suburbs of Zimbabwe's capital with new typhoid conjugate vaccine (TCV). At least 12.4 million children worldwide are categorized as 'zero-dose', living in missed communities that cannot access many essential services, including health care.

Key features of the study:

  • This report provides an in-depth analysis of the global typhoid fever vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global typhoid fever vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global typhoid fever vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global typhoid fever vaccines market

Detailed Segmentation:

  • Global Typhoid Fever Vaccines Market, By Vaccine Type:
    • Live Attenuated Vaccine
    • Capsular Polysaccharide Vaccines
    • Conjugate Vaccine
    • Others
  • Global Typhoid Fever Vaccines Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Typhoid Fever Vaccines Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • GlaxoSmithKline Plc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Sanofi SA
    • Bharat Biotech
    • Bio-Med Pvt. Ltd.
    • PT Bio Farma
    • PaxVax, Inc.
    • Shanghai Institute of Biological Products Co., Ltd.
    • Prokarium

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI2552

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Vaccine Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Novel Product Launch/Approval
  • PEST Analysis
  • Awareness Strategy
  • Reimbursement Scenario
  • Typhoid Fever Vaccines Shortage
  • Clinical Trial Analysis
  • Countries with High Number of Incidents of Snake Bites
  • Market Entry Challenges

4. Global Typhoid Fever Vaccines Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Typhoid Fever Vaccines Market, By Vaccine Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Live Attenuated Vaccine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Capsular Polysaccharide Vaccines
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Conjugate Vaccine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Typhoid Fever Vaccines Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Parental
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Typhoid Fever Vaccines Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • GlaxoSmithKline Plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Sanofi SA
  • Company Overview
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • Bharat Biotech
  • Company Overview
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • Bio-Med Pvt. Ltd.
  • Company Overview
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • PT Bio Farma
  • Company Overview
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • PaxVax, Inc.
  • Company Overview
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • Shanghai Institute of Biological Products Co., Ltd.
  • Company Overview
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • Prokarium
  • Company Overview
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!